Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Equivalence of Generic Brinzolamide vs Azopt in Glaucoma/Ocular Hypertension
NCT03896633Phase 2Completed
- Sponsor
- Bausch + Lomb
- Start
- Feb 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of brinzolamide in primary open-angle glaucoma (POAG) and ocular hypertension (2 arms), sponsored by Bausch + Lomb. Primary endpoint: Intraocular Pressure at 6 weeks. Started Feb 2018; status: completed.
02
Drugs
brinzolamide
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT03896633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896633.